Skip to content
Screener

Arcus Biosciences RCUS Business Segments — D&A

Similar metrics at other companies

OLP
OLPXReportable Segment — D&A
$13.32M-0.4%
V2X logo
VVXReportable Segment — D&A
$28.11M+0.3%
Anterix logo
ATEXReportable Segment — D&A
$103K+35.5%
DocuSign logo
DOCUReportable Segment — D&A
$32.21M+6.1%
Chewy logo
CHWYReportable Segment — D&A
$37M+23.3%
CWA
CWANReportable Segment — D&A
$29.56M+840%

Other financials

Income statement

See full
Revenue$41.0M-74.4%
Operating income-$96.0M-1,100%
Net income-$91.0M
EPS (diluted)-$0.72

Balance sheet

See full
Cash & equivalents$150.0M-39.5%
Total debt$114.0M+4.6%
Total equity$464.0M-15.5%
Total assets$924.0M-14.0%

Cash flow

See full
Operating cash flow-$119.0M+10.5%
CapEx-
Free cash flow-$119.0M+10.5%

Valuation

See full
Market cap$3.61B+259%
Enterprise value$3.57B+312%
P/S30.8×+27.0×

Profitability

See full
Operating margin-415.4%-756pp
Net margin-393.2%-663pp
FCF margin-406%

Returns & leverage

See full
Return on equity-90.8%+373pp
Debt / equity0.2×0.0×
Current ratio3.8×-0.7×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001724521-26-000044
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Late-stage development programs (1)5174111129
Early-stage development and preclinical programs (2)21383980
Compensation and personnel costs5861129128
Depreciation and amortization2255
Interest income, net(5)(8)(11)(18)
Other segment items (3)22264047
Partnership reimbursements(17)(33)(36)(71)
Segment net income (loss) and Consolidated net income (loss)$(91)$(219)$(112)

Item 1. Financial Statements

FAQ

What is Arcus Biosciences's business segments — D&A?
Arcus Biosciences (RCUS) reported business segments — D&A of $2M in Q2 2026.
How has Arcus Biosciences's business segments — D&A changed year-over-year?
Arcus Biosciences's business segments — D&A decreased by 0.0% year-over-year, from $2M to $2M.
What is the long-term trend for Arcus Biosciences's business segments — D&A?
Over 3 years (2022 to 2025), Arcus Biosciences's business segments — D&A has grown at a 18.6% compound annual growth rate (CAGR), from $6M to $10M.
What does business segments — D&A mean?
Represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the segment. This metric helps in understanding the capital intensity of the segment's infrastructure and intellectual property portfolio.

Ask your AI about Arcus Biosciences's business segments — d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude